
Pfizer and Janssen have decided to drop their investigational Alzheimer’s drug bapineuzumab after it failed a second late-stage study. The …

Pfizer and Janssen’s investigational Alzheimer’s drug bapineuzumab is no better than placebo, according to a new study. The Phase III …

Despite many years of relentless research efforts, Alzheimer’s disease, the most common form of dementia, remains impossible to cure. According …
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical
Claris reports visual acuity gains with experimental LSCD treatment
Amphista doses first patient in AML trial of protein degrader

